Progyny, Inc. (NASDAQ:PGNY) Shares Acquired by Vanguard Group Inc.

Vanguard Group Inc. lifted its holdings in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 0.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 8,692,132 shares of the company's stock after purchasing an additional 48,271 shares during the quarter. Vanguard Group Inc. owned about 10.21% of Progyny worth $149,939,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Signaturefd LLC boosted its stake in Progyny by 1,355.0% during the fourth quarter. Signaturefd LLC now owns 1,455 shares of the company's stock worth $25,000 after buying an additional 1,355 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Progyny by 341.4% in the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock worth $28,000 after acquiring an additional 1,246 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Progyny by 108.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock worth $51,000 after purchasing an additional 1,526 shares during the period. Caitlin John LLC increased its holdings in Progyny by 2,974.8% in the 4th quarter. Caitlin John LLC now owns 3,290 shares of the company's stock valued at $57,000 after purchasing an additional 3,183 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new stake in Progyny in the fourth quarter valued at approximately $74,000. 94.93% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Progyny Trading Up 0.4 %

Shares of PGNY stock traded up $0.08 on Friday, reaching $22.34. 855,876 shares of the stock were exchanged, compared to its average volume of 1,729,568. Progyny, Inc. has a twelve month low of $13.39 and a twelve month high of $34.92. The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of 38.52, a PEG ratio of 2.39 and a beta of 1.33. The business's 50 day moving average price is $22.01 and its 200 day moving average price is $18.68.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. JPMorgan Chase & Co. raised their price target on Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 28th. Bank of America lifted their target price on Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a research report on Tuesday, February 11th. BTIG Research raised shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price target on the stock in a research report on Monday, March 31st. Finally, Canaccord Genuity Group raised their price objective on shares of Progyny from $17.00 to $23.00 and gave the company a "hold" rating in a research note on Friday, February 28th. Eight equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $23.64.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.